Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab phase 3 trial in active psoriatic arthritis
jRCT2080224795Phase 3Completed
- Sponsor
- UCB
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of bimekizumab in psoriatic arthritis (PsA) (3 arms), sponsored by UCB. Started Jul 2019; status: completed.
02
Drugs
bimekizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on jRCT2080224795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224795.